- Home
- SER vs MAIA Comparison
SER vs MAIA Comparison
Compare SER & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- MAIA
- Stock Information
- Founded
- SER 2017
- MAIA 2018
- Country
- SER United States
- MAIA United States
- Employees
- SER N/A
- MAIA N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- MAIA Health Care
- Exchange
- SER Nasdaq
- MAIA Nasdaq
- Market Cap
- SER 47.5M
- MAIA 52.8M
- IPO Year
- SER 2018
- MAIA 2022
- Fundamental
- Price
- SER $4.73
- MAIA $1.85
- Analyst Decision
- SER
- MAIA
- Analyst Count
- SER 0
- MAIA 0
- Target Price
- SER N/A
- MAIA N/A
- AVG Volume (30 Days)
- SER 10.3K
- MAIA 356.4K
- Earning Date
- SER 11-12-2024
- MAIA 03-20-2025
- Dividend Yield
- SER N/A
- MAIA N/A
- EPS Growth
- SER N/A
- MAIA N/A
- EPS
- SER N/A
- MAIA N/A
- Revenue
- SER $3,157,500.00
- MAIA N/A
- Revenue This Year
- SER N/A
- MAIA N/A
- Revenue Next Year
- SER N/A
- MAIA N/A
- P/E Ratio
- SER N/A
- MAIA N/A
- Revenue Growth
- SER 2454.55
- MAIA N/A
- 52 Week Low
- SER $3.81
- MAIA $1.24
- 52 Week High
- SER $19.93
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- SER 48.48
- MAIA 44.20
- Support Level
- SER $4.80
- MAIA $1.83
- Resistance Level
- SER $5.64
- MAIA $1.94
- Average True Range (ATR)
- SER 0.23
- MAIA 0.15
- MACD
- SER 0.04
- MAIA 0.01
- Stochastic Oscillator
- SER 20.16
- MAIA 15.09
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.